SCHEMBL4740494

SCHEMBL4740494

O=C(O)CNC(=O)c1c(O)nc(-c2ccccc2)n(-c2ccccc2)c1=O

nearest known ligand 0.65

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.65
ALDH1A1 P00352 1/20 0.54
LMNA P02545 1/20 0.54
EGLN1 Q9GZT9 14/20 0.52
FTO Q9C0B1 2/20 0.47
KDM5B Q9UGL1 2/20 0.47
KDM2A Q9Y2K7 2/20 0.47
EGLN3 Q9H6Z9 2/20 0.46
KDM6B O15054 1/20 0.44
KDM4C Q9H3R0 1/20 0.44
KDM3A Q9Y4C1 1/20 0.44
MEN1 O00255 1/20 0.43
GAA P10253 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4992247 0.81 EGLN3 (0.62) ALDH1A1LMNAEGLN1EGLN3
SCHEMBL4997472 0.80 EGLN1 (0.57) HTTALDH1A1LMNAEGLN1FTO
SCHEMBL4992084 0.79 EGLN3 (0.46) HTTALDH1A1LMNAEGLN1FTO
SCHEMBL4989785 0.78 EGLN3 (0.60) ALDH1A1LMNAEGLN1EGLN3
SCHEMBL4737006 0.78 EGLN1 (0.52) HTTLMNAEGLN1EGLN3
SCHEMBL4997520 0.76 EGLN3 (0.59) EGLN1FTOKDM5BKDM2AEGLN3
SCHEMBL4742622 0.76 EGLN1 (0.42) HTTALDH1A1LMNAEGLN1FTO
SCHEMBL4996305 0.74 EGLN3 (0.59) EGLN1EGLN3
SCHEMBL4988688 0.74 EGLN3 (0.78) EGLN1EGLN3
SCHEMBL4883610 0.74 HTT (0.62) HTTALDH1A1LMNAMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO claimed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US claimed
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 HTT 2059/4885ALDH1A1 513/4885LMNA 3270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.